SHINE Technologies, LLC

SHINE Technologies, LLC is an advanced nuclear technology company headquartered in Janesville, Wisconsin, United States. The company's core mission is to deploy state-of-the-art fusion technology to address global challenges, serving as a scalable pathway to practical fusion energy and aiming to create a safer, healthier, and cleaner world.

SHINE employs a phased business strategy, leveraging its fusion technology for several revenue-generating applications. These include the production of critical medical isotopes, such as molybdenum-99 (Mo-99) for diagnostic imaging and lutetium-177 (Lu-177) for targeted cancer therapies. Additionally, the company provides neutron testing services for industrial inspection, radiation effects testing for defense and aerospace components, and conducts fusion material research. SHINE is also actively involved in pioneering nuclear waste recycling technologies to enhance the sustainability of nuclear energy.

Founded by Greg Piefer, who also serves as CEO, SHINE Technologies is privately held. In February 2026, the company completed a $240 million Series E equity funding round, led by NantWorks, bringing its total capital raised to over $1 billion. This round also saw Dr. Patrick Soon-Shiong, founder of NantWorks, join SHINE's Board of Directors. Further solidifying its market position, SHINE received a conditional commitment for a $263 million loan from the U.S. Department of Energy in April 2026 to support the completion of its Chrysalis medical isotope production facility. The company also recently acquired Lantheus's isotope distribution business. SHINE's long-term vision is to reduce global reliance on aging fission reactors for medical isotope production and ultimately commercialize fusion energy for power generation.